What happened with CTKB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cytek Biosciences supplies equipment that researchers use to study cells. Pharmaceutical and biotechnology companies, universities, government institutions and contract research organizations buy its systems directly or through distributors. Its core technology measures the full range of fluorescent light emitted by labeled cells, allowing researchers to analyze multiple cell characteristics together. SpectroFlo software supports the instruments and their data collection.
Product sales provide most revenue, chiefly from instruments and accessories rather than reagents. Cytek Aurora, Northern Lights, Aurora CS and Aurora Evo systems account for much of the business. After installation, customers also pay for reagents, maintenance, repairs and service contracts once warranties expire. The installed instrument base supports these continuing sales; Cytek aims to build more recurring consumables revenue from it.
Academic and government customers supply a large share of revenue, making purchases dependent partly on research budgets and government funding. Production also relies on limited or sole-source suppliers of lasers and semiconductors, including laser supplier Coherent.
In the United States, Cytek primarily sells products for research, not clinical diagnosis; entering clinical markets requires FDA authorization. Northern Lights-CLC is available for clinical use only in China and the European Union. U.S. export controls also require licenses for certain cell-analysis products sold to destinations including China and can prohibit sales to sanctioned parties.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cytek's results depend on research laboratories' instrument budgets and demand for servicing installed instruments, while privately held Miltenyi Biotec adds competition and Coherent supplies important lasers.
Standard BioTools competes with Cytek for researchers measuring many markers on individual cells: its CyTOF systems use metal-tagged antibodies, while Cytek's spectral flow instruments measure fluorescent signals. Watch demand for CyTOF instruments and reagents among academic and biopharmaceutical researchers as a sign of interest in this alternative approach.
Waters directly competes with Cytek in cell analysis through its Biosciences and Diagnostic Solutions business, which names Cytek as a principal rival. For this tie, watch that business's laboratory equipment rather than Waters' broader sales of chemical-analysis instruments, consumables and support.
Danaher's Beckman Coulter business competes with Cytek for laboratories buying instruments to analyze cells. That equipment business is the relevant rivalry to watch within Danaher's much broader biotechnology, life-sciences and diagnostics operations.
Bio-Rad competes with Cytek for research and biopharmaceutical laboratories buying instruments and reagents to characterize cells. Its Life Science business is the relevant line to watch, rather than Clinical Diagnostics, which accounted for about 60% of its 2025 net sales.
Thermo Fisher competes with Cytek for research and clinical laboratories buying cell-analysis tools. Those products are only part of Thermo Fisher's much larger scientific-products and services business, so its company-wide results are a less focused view of Cytek's market.
Agilent competes with Cytek for life-sciences laboratories buying cell-analysis tools, but sells a much broader range of instruments. Its CrossLab consumables can serve customers regardless of their instrument choice, so that revenue does not necessarily signal wins for Agilent instruments over Cytek.
10x Genomics and Cytek both depend on academic and biopharmaceutical spending on single-cell research, though they sell different analysis platforms. Demand for 10x's Chromium instruments and related consumables offers a view of spending by research customers that substantially overlap with Cytek's.
Revvity and Cytek share exposure to research funding and drug-development spending: Revvity sells cell-research tools to the institutions and pharmaceutical and biotechnology customers that also buy Cytek's cell-analysis systems. Watch Revvity's Life Sciences business for this demand, rather than its hospital and medical-laboratory diagnostics business.
BD competes with Cytek in equipment sold to cellular-research laboratories and also lets Cytek use certain patents in return for royalties on specified products. Watch the disclosed plan to separate BD's Biosciences and Diagnostic Solutions business and combine it with Waters, which shifts where this equipment rivalry resides.
Waters Corp earningsWAT
Waters' report, especially laboratory equipment in its Biosciences and Diagnostic Solutions business, will show demand for cell-analysis instruments—the market where Waters directly competes with Cytek Biosciences, Inc.
Focus on laboratory equipment in Waters' Biosciences and Diagnostic Solutions business, not Waters' total sales as a proxy for cell-analysis demand. Stronger equipment sales would show that laboratories are still buying these instruments, supporting demand in Cytek Biosciences, Inc.'s market. Weaker sales would point to softer instrument spending in the same market, but would not prove that Cytek's own sales fell.
Revvity, Inc. earningsRVTY
Revvity's Life Sciences business serves research institutions and pharmaceutical and biotechnology companies that also buy Cytek Biosciences, Inc.'s cell-analysis systems, so its results offer a read on those customers' research and drug-development spending.
Watch sales in Revvity's Life Sciences business, not its hospital and medical-laboratory diagnostics business. Strength there would suggest research and drug-development spending by customers shared with Cytek Biosciences, Inc. is holding up, supporting instrument purchases and follow-on service demand. Weakness would point to tighter spending by those customers and greater pressure on Cytek's equipment and service demand.
Cytek Biosciences, Inc. earningsThis company
Cytek Biosciences, Inc.'s report will show whether instrument and accessory sales are joining service revenue as sources of growth, or whether the business still relies mainly on services for its installed instruments.
Read product revenue alongside service revenue, then check product gross margin—the share of product revenue left after direct costs. Product revenue rising with margin holding steady, while service revenue also grows, would show that instrument demand and support for the installed base are both contributing. If product revenue or margin falls while only services grow, service from existing instruments has not made up for weak new-system sales.
